Document:

exv10w3

Exhibit 10.3

REVENUE SHARING DISTRIBUTION AGREEMENT

This Agreement is made and entered into as of the latest date set forth on the signature lines
below (the “Effective Date”) by and between Oculus Innovative Sciences, Inc., a Delaware
corporation having a place of business at 1129 No. McDowell Boulevard, Petaluma, California, USA
94954 (“Company”), and VetCure, Inc., a California corporation having a place of business at 3546
N. Riverside Ave, Rialto, CA 92377 (“Distributor”).

     WHEREAS Company has developed proprietary technology and know-how known as the Vetericyn Wound
Care Spray (“Vetericyn”) which the Company distributes and sells in the form of liquid solutions,
as further identified in Exhibit A to this Agreement, and

     WHEREAS Distributor desires to distribute Vetericyn in the Territory (as hereinafter defined).

     NOW THEREFORE in consideration of the mutual promises and undertakings of the parties hereto
the parties agree as follows:

     1. Definitions.

          1.1 “Change in Control” shall mean (a) any consolidation or merger of either party with or
into any other corporation or other entity or person, or any other corporate reorganization, in
which the stockholders of such party immediately prior to such consolidation, merger or
reorganization, own less than fifty percent (50%) of such party’s voting power immediately after
such consolidation, merger or reorganization, or any transaction or series of related
transactions to which either is a party in which in excess of fifty percent (50%) of such party’s
voting power is transferred; or (b) a sale, lease or other disposition of all or substantially
all the assets of either party.

          1.2 “Confidential Information” means information of a party, which information is
conspicuously marked with “Confidential”, “Proprietary” or other similar legend. If
Confidential Information is orally disclosed or it is observed, it shall be identified as such at
the time of disclosure or observation and a brief written description and confirmation of the
confidential nature of the information shall be sent to the recipient within thirty (30) days
after the disclosure. The Solution Specifications, quantities, schedules and pricing, projections
and business plans shall be considered Confidential Information hereunder whether disclosed
orally or in writing, or whether or not marked “Confidential” or “Proprietary.”

          1.3 “Intellectual Property Rights” means all intellectual property rights worldwide arising
under statutory or common law or by contract and whether or not perfected, now existing or
hereafter filed, issued, or acquired, including all (a) patent rights; (b) rights associated with
works of authorship including copyrights and mask work rights; (c) trademarks, service marks,
trade dress and trade names; (d) rights relating to the protection of trade secrets and
confidential information; and (e) any right analogous to those set forth herein and any other
proprietary rights relating to intangible property.

          1.4 “Markets” means the animal health markets solely for use in the treatment of all types
of animals (non-humans) within the Territory.

 

 

          1.5 “Purchase Order” shall mean an offer from Distributor received by Company, whether in
written or other form, or in electronic form, to purchase or schedule delivery of a specified
amount of Solutions that complies with the requirements set forth in this Agreement.

          1.6 “Regulatory Approvals” means any and all approvals, applications, registrations,
licenses, certifications and other requirements imposed by any governmental agency or other
entity exercising any regulatory or other governmental or quasi-governmental authority.

          1.7 “Company’s Technology” means Company’s proprietary technology and know-how known as the
Microcyn Technology, used for (among other things) veterinary applications.

          1.8 “Solution(s)” means the liquid solutions based on Company’s Microcyn Technology which
are to be provided by Company under this Agreement as Vetericyn Wound Care Spray, as further
described in Exhibit A. From time to time, the Company may introduce new products and
packaging, including, but not limited to, otic cleanser, gels, shampoos, etc., based on the
Microcyn Technology platform and new packaging configurations. Distributor will be granted
exclusive distribution rights for these new products in the Market during the Term and within the
Territory. The parties intend to work in good faith to finalize pricing, packaging and labeling
regarding these new products in the future.

          1.9 “Solution Specifications” means the specifications for the Solutions as set forth in
Exhibit B.

          1.10 “Territory” shall mean the United States of America.

     2. Purchases and Solutions.

          2.1 General. This Agreement establishes the terms and conditions on which Company
will sell to Distributor the Solutions. This Agreement shall not be modified, supplemented or
interpreted by any trade usage or prior course of dealing not made a part of this Agreement by
its express terms.

          2.2 Appointment. Subject to all the terms and conditions of this Agreement, Company
hereby appoints Distributor for the term of this Agreement as the exclusive distributor of the
Solutions only within the Market and only within the Territory. Distributor may distribute
Solutions only to persons and entities located and taking delivery within the Territory .
Furthermore, Solution distributed by Distributor for further distribution may be distributed only
through subdistributors who are bound in writing for Company’s benefit to all the restrictions on
Distributor contained in this Agreement. Nothing in this Agreement shall be construed as limiting
in any manner Company’s marketing or distribution activities or its appointment of other dealers,
distributors, licensees or agents outside the Market and/or outside the Territory.

          2.3 Shipment Terms and Costs. Solution is delivered DDP, Delivered Duty Paid, from
the Company’s manufacturing plant in Zapopan, Mexico to Distributor’s warehouse in Rialto,
California.

 

 

          2.4 Purchase Order and Forecast. On a quarterly basis, Distributor shall provide a
non-binding, rolling forecast of purchases of Solutions for the next six (6) months after the
period covered by the Purchase Order.

          2.5 Purchase Orders. All Purchase Orders shall contain such pricing, requested
shipment schedule, delivery address, requested carrier and quantity terms as set forth in
Exhibit A.

     When acknowledgement of receipt and acceptance of the Purchase Order is made by Company
(either by written notice or by shipment of the Solutions covered by the Purchase Order), the
Purchase Order shall be deemed a commitment to purchase and sell the Solutions pursuant to the
terms of this Agreement.

          2.6 Pricing. The Solution prices are set forth in Exhibit A and shall be
payable in US Dollars.

          2.7 Payment Terms. Payment terms are thirty (30) days net for OBP (defined below).
All payments related to the Revenue Sharing (also defined below) portion are due thirty (30) days
after month end for which the Revenue Sharing calculation applies.

          2.8 Minimum Purchase. Minimum ordering quantities are set forth in
Exhibit A. No orders shall be accepted, unless such orders are at least equal to or
greater than the minimum quantities set forth in Exhibit A.

     3. Delivery and Acceptance.

          3.1 Delivery of Solution. Delivery of Solution shall be DDP, Delivered Duty Paid,
from the Company’s manufacturing plant in Zapopan, Mexico to Distributor’s warehouse in Rialto,
California. Shipment dates are approximate and are subject to change.

          3.2 Packaging. Company shall package the Solutions for shipment to Distributor in
the manner customarily used by Company, unless Distributor requires different packaging
specifications, in which case any such different packaging shall be at Distributor’s expense.
Distributor will provide such reasonable specifications to Company in writing within thirty (30)
days of the Effective Date. After execution of this Agreement, Distributor will, at its own
expense, begin studying all necessary steps to conduct final finished bottlling and labeling
(“Packaging”) of Vetericyn in Distributor’s facility. The Company will, at its own expense,
begin studying all necessary steps to manufacture the Solution in Petaluma, California and ship
to Distributor in bulk. Distributor intends to target certain Packaging and Solution pricing not
to exceed $2.00 per bottle. If the costs of Packaging and Solution pricing are greater than
$2.00 per bottle, which includes transportation and duties, if any, then Distributor will absorb
any additional costs over $2.00 per bottle. If the costs of Packaging and Solution are less than
$2.00 per bottle, then any savings will be shared equally between the parties. Upon achieving
all necessary regulatory approvals necessary for Packaging medical devices, Distributor will have
the right to Package the Solution for the Market in the Territory. The Company will conduct
periodic audits, with reasonable prior notice, of Distributor’s Packaging facility in an effort
to ensure Distributor complies with appropriate regulatory requirements for final finished
Packaging. The parties agree to work in good faith
to create a similar Revenue Sharing mechanism, as described in Exhibit A, upon
transfer of Packaging to Distributor.

 

 

          3.3 Future Manufacturing Rights. Upon achieving a certificate of compliance under
Good Manufacturing Practices (“GMP”) to Package medical devices under US Food and Drug
Administration rules, the parties agree to work in good faith to study Distributor’s
manufacturing capabilities under the following scenario. Distributor would provide a secure
manufacturing area within Distributor’s facility solely to house the Company’s proprietary
manufacturing line. Distributor would further reimburse all salary and related employment costs
for a Company employee, if deemed necessary by the parties, to maintain and operate the Company’s
manufacturing line within Distributor’s facility. Any potential costs savings that result from
the transfer of manufacturing to Distributor’s facility would be split evenly between the Company
and Distributor. For purposes of clarity, any transfer of manufacturing rights will only occur
upon written mutual agreement, or pursuant to Section 10.3.

          3.4 Risk of Loss or Damage. Title and risk of loss will be transferred to
Distributor upon delivery of Solutions by Company. Distributor will also bear the risk of loss
with respect to any Solutions rejected by Distributor until received by Company in Petaluma,
California, or another location by mutual agreement.

          3.5 Delivery Performance. Company may make partial deliveries of the Solutions under
this Agreement. Partial deliveries will be separately invoiced by Company and paid for by
Distributor without regard to subsequent deliveries.

          3.6 Cancellation; Rescheduling. Distributor may not cancel or reschedule any
shipment under a Purchase Order once the Purchase Order is accepted by Company.

          3.7 Solution Acceptance. All Solutions will be subject to final inspection and
acceptance by Distributor within seven (7) working days after receipt. Distributor may only
reject Solutions if the Solutions shipped by Company did not materially conform to the Solution
Specifications at the time of shipment by Company. In any event, use of the Solutions by
Distributor or its customers, or the failure by Distributor to return the Solutions within
fourteen (14) working days following delivery of such Solutions shall constitute acceptance by
the Distributor. Any Solutions properly rejected will be returned to Company in accordance with
the return procedures set forth in Article VI with respect to warranty claims.

          3.8 Force Majeure. Neither party shall  be liable for nonperformance or delay in
performance (other than of obligations regarding payment of money or confidentiality) caused by
any event reasonably beyond the control of such party including, but not limited to wars,
hostilities, revolutions, riots, civil commotion, national emergency, strikes, lockouts,
epidemics, fire, flood, earthquake, force of nature, explosion, embargo, or any other Act of God,
or any law, proclamation, regulation, ordinance, or other act or order of any court, government
or governmental agency.

 

 

     4. Certain Obligations.

          4.1 Distribution Efforts. Distributor shall use commercially reasonable efforts to
successfully market the Solutions in the Market in the Territory on a continuing basis and to
comply with good business practices and all laws and regulations relevant to this Agreement or
the subject matter hereof. In its distribution efforts, Distributor will use mutually agreed
upon names for the Solution; provided that all advertisements and promotional materials shall be
subject to mutual written consent of both parties, which approval shall not be unreasonably
withheld, and, provided further, that no other right to use any name or designation is granted by
this Agreement.

          4.2 Compliance with Laws. Both parties shall conduct their respective businesses in
accordance with all laws and regulations. Without limiting the foregoing, Distributor shall not
market or sell any Solution except in compliance with the Regulatory Approvals and all applicable
laws and regulations.

          4.3 Exclusivity and Use of Solutions. Distributor is the exclusive distributor in
the Territory and purchase of Solution is solely for use by Distributor in the Markets.
Distributor shall not market, distribute or sell the Solution on a stand-alone basis or in any
market other than the Markets.

          4.4 Support. Subject to Company’s scheduling and personnel constraints, Company
will provide to Distributor reasonable engineering, research and development support and access
to its personnel as needed for use of the Solution in the Markets.

          4.5 Branding of Solution. Both parties will work in good faith to use the other’s
trademarks and brand names for labeling and marketing efforts.

          4.6 Equity Compensation. In exchange for Distributor’s commitment to its marketing
efforts and other good and valuable consideration, the Company will issue to the Distributor
433,275 shares of its common stock. Such issuance will depend on the Company’s satisfaction
that such issuance complies with federal and state securities laws and with the rules and
regulations for the trading market on which the Company’s stock trades. The Distributor agrees
to provide such information as reasonably requested by the Company to establish such compliance.
The Company will issue such shares of common stock within 10 business days of the execution of
this agreement to such individuals or entities as directed by the Distributor or as otherwise
decided by the parties in writing. The shares of common stock will be issued pursuant to a
private placement and will bear a restrictive legend. The shares of common stock will not have
registration rights however the Company may, in its sole discretion, register such shares of
common stock.

     5. Ownership.

          5.1 Company’s IP. Company is and shall be the sole and exclusive owner of all
Intellectual Property Rights in and to the Solutions and Company’s Technology, including, without
limitation, its Microcyn Technology, and any and all inventions, technology, know-how and other
intellectual property made, conceived, created, reduced to practice or otherwise developed as
part of Company’s services pursuant to Article IV of this Agreement, and all improvements,
enhancements, modifications and derivatives of any of the foregoing (collectively, “Company’s
IP”).

 

 

          5.2 No Reverse Engineering. Distributor acknowledges that the Solutions contain the
valuable trade secret information of Company and other proprietary information of Company.
Accordingly, Distributor agrees that it will not, at any time during the term of this Agreement
or thereafter, reverse engineer or otherwise attempt to discern the trade secret information of
the Solutions, nor will Distributor permit any third party to do any of the foregoing. Company
acknowledges that the Distributor’s Process contains the valuable trade secret information of
Distributor and other proprietary information of Distributor. Accordingly, Company agrees that
it will not, at any time during the term of this Agreement or thereafter, reverse engineer or
otherwise attempt to discern the trade secret information of the Distributor’s Process, nor will
Company permit any third party to do any of the foregoing.

          5.3 IP Warranty. The Company is the legal and beneficial owner of all right, title
and interest in and to the Intellectual Property, the Solutions and the Company Technology,
having good title hereto, free and clear of any and all mortgages, liens, security interest and
charges, and no person or entity has or shall have any claim of ownership with respect to the
Intellectual Property, the Solutions or the Company Technology; The Intellectual Property is
subsisting and is not invalid or unenforceable, in whole or in part; Company has not previously
assigned, transferred, conveyed or otherwise encumbered any right, title or interest in the
Intellectual Property, the Solutions or the Company Technology the subject of this Agreement and
has not granted to any third party any license to use the Intellectual Property, Solutions or the
Company Technology in any manner inconsistent with or in conflict with any provisions of this
Agreement or the rights of Distributor under this Agreement, or any covenant not to sue for any
such use; Neither the Intellectual Property, the Solutions nor the Company Technology nor the
disclosing, copying, making, using or selling of such Intellectual Property, Solutions or Company
Technology, or products or services embodying such Intellectual Property, Solutions of Company
Technology, violates, infringes or otherwise conflicts or interferes with any copyright, trade
secret, trademark, service mark, patent or any other intellectual property or proprietary right
of any third party; There are no claims, judgments or settlements relating to the Intellectual
Property, the Solutions or the Company Technology to be paid by the Company, and no claim has
been brought by any person or entity alleging that the Intellectual Property, the Solutions or
the Company Technology or the disclosing, copying, making, using or selling of such Intellectual
Property, Solutions or Company Technology or products or services embodying such Intellectual
Property, Solutions or Company Technology, violates, infringes or otherwise conflicts or
interferes with any copyright, trade secret, trademark, service mark, patent or any other
intellectual property or proprietary right of any third party; and the Company does not know of
any infringement by others of the Intellectual Property.

     6. Limitation On Liability And Remedies.

          6.1 Company Limited Warranty; Limitation of Remedies.

               (a) Company warrants that each Solution delivered will, under normal use and
conditions, substantially conform to the applicable Solution Specifications for a period of
one (1) to two (2) years, in conformity with the various products label claims regarding
shelf-life, after the specific Solution has shipped ex-works. This limited warranty does
not cover the results of accident, abuse,
misapplication, vandalism, acts of God, use contrary to specifications or instructions,
or modification by anyone other than Company.

 

 

               (b) Company’s entire liability and Distributor’s exclusive remedy, except for the
indemnity obligations as set forth in Section 7.2, which are in addition to the remedies set
forth in this Section 6.1, shall be replacement of the materially non-conforming Solutions.
Distributor may reject and return such non-conforming Solutions for modification or
replacement by Company provided that Distributor must first obtain a Return Material
Authorization from Company. Company shall issue a Return Material Authorization (“RMA”)
within two (2) business days after Distributor’s request. Any additional terms of the RMA
procedure shall be mutually agreed to between the parties. Distributor shall include the RMA
number with all returns. Distributor shall return all such non-conforming Solutions to
Company within fifteen (15) days of Distributor’s receipt of such Solutions.

               (c) Company is liable for all transit costs associated with replacement of
non-conforming Solution. If the Company intends to destroy any non-conforming Solution,
such costs are the responsibility of the Company.

               (d) If modification or replacement is not reasonably possible, then Company may elect
to refund to Distributor an amount equal to the purchase price for the non-conforming
Solutions, and such refund shall be Distributor’s entire remedy. Any replacement Solution
will be warranted for the remainder of the original warranty period. Company shall not be
responsible for any labor costs or other costs Distributor incurs incident to the
replacement of any non-conforming Solution.

               (e) If Company determines that any returned Solution conformed to the warranty, Company
will return the Solution to Distributor at Distributor’s expense, freight collect, along
with a written statement setting forth Company’s conclusion that the returned Solution was
not defective, and Distributor agrees to pay Company’s reasonable cost of handling and
testing the returned Solution.

               (f) EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE VI, THE SOLUTIONS ARE PROVIDED
“AS-IS” WITHOUT WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND AGAINST
INFRINGEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE VI, COMPANY DOES NOT WARRANT
THAT THE SOLUTIONS WILL MEET SPECIFIC REQUIREMENTS.

          6.2 Consequential Damages Waiver. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE
OTHER PARTY OR ITS CUSTOMERS FOR ANY INCIDENTAL, SPECIAL, CONSEQUENTIAL, PUNITIVE OR INDIRECT
DAMAGES, INCLUDING BUT NOT LIMITED TO ANY LOST PROFITS OR LOST SAVINGS ARISING OUT OF THE USE OR
INABILITY TO USE THE SOLUTIONS OR OTHERWISE ARISING OUT OF OR RELATED TO THIS AGREEMENT.

 

 

          6.3 Limitation of Liability. COMPANY’S AGGREGATE LIABILITY UNDER OR ARISING OUT OF
THIS AGREEMENT FOR ANY CLAIM, WHETHER BASED ON CONTRACT, TORT OR OTHERWISE, SHALL BE LIMITED,
EXCEPT FOR THE INDEMNITY OBLIGATIONS IN SECTION 7.2, WHICH ARE IN ADDITION TO THE REMEDIES SET
FORTH IN THIS SECTION 6.3, TO AN AMOUNT EQUAL TO THE AMOUNT PAID BY DISTRIBUTOR TO COMPANY UNDER
THIS AGREEMENT FOR THE SOLUTIONS THAT ARE THE SUBJECT OF THE LIABILITY IN THE SIX-MONTH PERIOD
IMMEDIATELY PRECEDING THE DATE ON WHICH THE CLAIM AROSE. DISTRIBUTOR’S AGGREGATE LIABILITY
UNDER OR ARISING OUT OF THIS AGREEMENT FOR ANY CLAIM, WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE, SHALL BE LIMITED TO THE AMOUNT OF COVERAGE REQUIRED UNDER THIS SECTION 6.3. EACH
PARTY SHALL NAME THE OTHER PARTY AS AN ADDITIONAL INSURED IN ITS LIAIBLITY INSURANCE COVERAGE AND
EACH PARTY SHALL MAINTIAN A MINIMUM OF TWO ($2,000,000) MILLION DOLLAR LIABILITY INSURANCE
COVERAGE.

     7. Indemnification.

          7.1 Distributor’s Indemnity. Distributor agrees that it will, at its own expense,
defend all suits or proceedings instituted against Company arising out of any marketing, sale or
use or off-label use of the Solution in the Markets by Distributor.

          7.2 Company’s Indemnity. The Company agrees that it will, at its own expense, defend
all suits or proceedings instituted against the Distributor arising out of any marketing, sale or
on-label use of the Company’s products in the non-Markets. The Company further agrees that it
will, at it own expense, indemnify and hold harmless for the benefit of Distributor and its
officers, directors, shareholders, for any liability or damage to Distributor in the event any
warranties of Company are inaccurate or false, any product liability claims regarding the
Solutions, or any infringement or threatened infringement of the Intellectual Property.

     8. Confidential Information

          8.1 Ownership of Confidential Information. Both parties are and shall remain the
owner of its Confidential Information. Nothing contained in this Agreement shall be construed as
granting any rights by license or otherwise to such Confidential Information.

          8.2 Agreement to Maintain Confidentiality. Both parties shall take all reasonable
steps to ensure that it and its agents maintain the confidentiality of the Confidential
Information.

          8.3 Agreement Not to Use or Disclose. Except as provided in this Agreement, neither
party shall  disclose to any other person or entity Confidential Information of the disclosing
party or use such Confidential Information for any purpose other than the purposes expressly
authorized under this Agreement.

          8.4 Specific Performance. The parties recognize and agree that any breach by the
receiving party of its obligations contained in this Article VIII would cause irreparable harm to
the disclosing party such that the disclosing party could not be compensated for the
harm by money damages alone. Therefore, the parties agree that the provisions of this
Article VIII shall be enforceable by specific performance, including injunctive relief.

 

 

     9. Term and Termination.

          9.1 Term. This Agreement shall be effective and in full force from the Effective
Date for a period of ten (10) years and shall automatically renew for successive five (5) year
terms, unless terminated earlier pursuant to this Section 9.

          9.2 Termination for Cause. Either party will have the right to terminate this
Agreement for cause upon thirty (30) days’ prior written notice to the other party of a material
breach of this Agreement by the other party that remains uncured during such thirty (30) day
period or if any representation or warranty is determined to be false or misleading.

          9.3 Effect of Termination.

               (a) Upon the termination of this Agreement for any reason, each party shall retain
ownership of its respective Confidential Information and shall return to the other party all
of the Confidential Information received from the other party up to the time of termination.

               (b) Upon termination of this Agreement, Distributor may elect to (i) pay to Company any
amounts due under this Agreement or (ii) return to the Company any unpaid for Solution.

               (c) If either party terminates this Agreement for cause, then, the other party may
elect to (i) continue to supply, or require the Company to continue to supply, Solutions to
Distributor under Purchase Orders that Company accepted prior to the effective date of
termination and Distributor agrees to pay Company the purchase price for such Solutions or
(ii) cancel all such Purchase Orders and neither party will have liability for such
cancellation.

               (d) Neither Company nor Distributor shall be liable to the other for compensation,
reimbursement or damages for the loss of prospective profits, anticipated sales or goodwill
as a result of the termination of this Agreement in accordance with the terms of Section 9.2
or Section 9.3.

          9.4 Survival. Upon the expiration, or the termination for any reason, of this
Agreement, the rights and obligations of the parties under Sections 2.6, 2.7, 3.7, 3.8, 4.1, 9.4,
9.5 and Articles 1,5,6,7 and 8 shall survive and remain in effect.

     10. Miscellaneous.

          10.1 Notices. All notices shall be deemed given by fax, and addressed as set forth
at the signature line below or to such other address as the party to receive the notice or
request so designates by written notice to the other.

          10.2 Assignment and Subcontracting. This Agreement and all rights and obligations
hereunder are personal to the parties hereto and shall not be assigned by either

 

 

party to any third party without the prior written consent thereto by the other party except
that Company may assign this Agreement to an affiliate or to a successor to all or substantially
all of the Company’s assets or to a majority of Company’s voting stock. This Agreement shall
benefit and be binding upon the parties to this Agreement and their respective permitted
successors and assigns.

          10.3 Change of Control.  Within sixty (60) days of a Change in Control at the
Company, and notwithstanding any provision of this Agreement to the contrary, including without
limitation Section 3.3, Distributor may elect at its own expense, to immediately transfer (by way
of a non-exclusive license) one or more of the Company’s manufacturing lines that produce the
Vetericyn formula for the Solutions.  Upon the election to transfer, Distributor would have the
exclusive right to manufacture and Package Vetericyn or any derivative thereof, in the Market
during the Term. In consideration, the Company, or its successors, would receive a one-time,
nonrefundable payment for the manufacturing lines(s) on a mutually agreed upon price, in any
event not to exceed the Company’s original cost for such manufacturing line(s) and a perpetual
ten percent (10%) royalty on net sales related to the sales of Vetericyn or any derivative product
thereof, for the Term. The Company, or its successors, would agree to provide, at Distributor’s
expense, commercially reasonable technical and other assistance to Distributor to facilitate the
transfer process. 

          10.4 Waiver. No term or condition of this Agreement shall be deemed waived unless
such waiver is in a writing executed by the party against whom the waiver is sought to be
enforced. Failure or delay in the exercise of any right, power or privilege hereunder shall not
operate as a waiver thereof or of any subsequent failure or delay.

          10.5 Governing Law, Jurisdiction, Venue. This Agreement is made under and in all
respects shall be interpreted, construed and governed by and in accordance with the Laws of the
State of California. Sole and exclusive jurisdiction in any case or controversy arising under
this Agreement or by reason of this Agreement shall be with the Sonoma County Superior Court or
the United States District Court for the Northern District of California, and for this purpose
each party hereby expressly and irrevocably consents to the exclusive jurisdiction of such
courts.

          10.6 Severability. If any of the provisions of this Agreement in any way violate or
contravene any laws applicable to this Agreement, such provision shall be deemed not to be a part
of this Agreement and the remainder of this Agreement shall remain in full force and effect. In
such event, the parties agree to negotiate in good faith to substitute legal and enforceable
provisions that most nearly effect the original intent of the severed provision.

          10.7 Subject Headings. The captions and headings used herein are intended for
convenience only, and shall not affect the construction or interpretation of any section or
provision of this Agreement.

          10.8 Entire Agreement; Amendments. This Agreement, including Exhibits A and B
hereto, constitutes the entire understanding and agreement of the parties related to the subject
matter hereof, and supersedes any and all prior or contemporaneous offers, negotiations,
agreements and/or understandings, written or oral, as to such subject matter. Except as provided
herein, no amendment, revision or modification of this Agreement shall be
effective or binding unless made in writing and signed by the party against whom enforcement
is sought.

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered
as of the date transcribed below.

	 	 	 	 	 	 	 	 	 
	COMPANY:	 	DISTRIBUTOR:	 	 
	OCULUS INNOVATIVE SCIENCES, INC.	 	VETCURE, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	BY:

	 	/s/ Hojabr Alimi	 	BY:	 	/s/ Robert Burlingame	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	TITLE:

	 	CEO and Chairman	 	TITLE:	 	CEO	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	DATE:

	 	January 26, 2009	 	DATE:	 	January 26, 2009	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	ADDRESS: 1129 No. McDowell Boulevard	 	ADDRESS:	 	 
	Petaluma, CA 94954	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	PHONE: (___)

	 	 	 	PHONE: (___)	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	FAX: (___)

	 	 	 	FAX: (___)exv4w1

Exhibit 4.1

Confidential

Execution Copy

 

OMNITURE, INC.

COMMON STOCK PURCHASE AGREEMENT

January 27, 2009

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	SECTION 1 AUTHORIZATION, SALE AND ISSUANCE
	 	 	1	 
	 
	 	 	 	 
	1.1 Authorization
	 	 	1	 
	1.2 Sale and Issuance of Shares
	 	 	1	 
	 
	 	 	 	 
	SECTION 2 CLOSING DATES AND DELIVERY
	 	 	2	 
	 
	 	 	 	 
	2.1 Closing
	 	 	2	 
	2.2 Delivery
	 	 	2	 
	 
	 	 	 	 
	SECTION 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	 	 	2	 
	 
	 	 	 	 
	3.1 Organization; Standing and Power; Charter Documents; Significant Subsidiaries
	 	 	2	 
	3.2 Capital Structure
	 	 	3	 
	3.3 Authority; Non-Contravention; Necessary Consents
	 	 	4	 
	3.4 SEC Filings; Financial Statements
	 	 	4	 
	3.5 Absence of Certain Changes or Events
	 	 	5	 
	3.6 Compliance
	 	 	5	 
	3.7 Litigation
	 	 	5	 
	3.8 Brokers’ and Finders’ Fees
	 	 	6	 
	 
	 	 	 	 
	SECTION 4 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR
	 	 	6	 
	 
	 	 	 	 
	4.1 No Registration
	 	 	6	 
	4.2 Investment Intent
	 	 	6	 
	4.3 Investment Experience
	 	 	6	 
	4.4 Speculative Nature of Investment
	 	 	6	 
	4.5 Access to Data
	 	 	6	 
	4.6 Accredited Investor
	 	 	7	 
	4.7 Residency
	 	 	7	 
	4.8 Rule 144
	 	 	7	 
	4.9 Authorization
	 	 	7	 
	4.10 Brokers or Finders
	 	 	7	 
	4.11 Tax Advisors
	 	 	7	 
	4.12 Representations by Non-United States persons
	 	 	7	 
	 
	 	 	 	 
	SECTION 5
	 	 	8	 
	 
	 	 	 	 
	5.1 Restrictions on Transfer
	 	 	8	 
	5.2 Standstill
	 	 	8	 
	5.3 Market Standoff
	 	 	9	 
	5.4 Restrictive Legends
	 	 	10	 
	5.5 Notice of Proposed Transfers
	 	 	11	 
	 
	 	 	 	 
	SECTION 6 CONDITIONS TO INVESTOR’S OBLIGATIONS TO CLOSE
	 	 	12	 
	 
	 	 	 	 
	6.1 Representations and Warranties
	 	 	12	 
	6.2 Covenants
	 	 	12	 
	6.3 Qualifications
	 	 	12	 
	6.4 Closing Deliverables
	 	 	12	 

i

 

TABLE OF CONTENTS
(continued)

	 	 	 	 	 
	 	 	Page
	SECTION 7 CONDITIONS TO COMPANY’S OBLIGATION TO CLOSE
	 	 	13	 
	 
	 	 	 	 
	7.1 Representations and Warranties
	 	 	13	 
	7.2 Covenants
	 	 	13	 
	7.3 Compliance with Securities Laws
	 	 	13	 
	7.4 Qualifications
	 	 	13	 
	7.5 Closing Deliverables
	 	 	13	 
	 
	 	 	 	 
	SECTION 8 MISCELLANEOUS
	 	 	13	 
	 
	 	 	 	 
	8.1 Amendment
	 	 	13	 
	8.2 Notices
	 	 	13	 
	8.3 Governing Law
	 	 	14	 
	8.4 Expenses
	 	 	14	 
	8.5 Disclosure
	 	 	14	 
	8.6 Survival
	 	 	15	 
	8.7 Successors and Assigns
	 	 	15	 
	8.8 Entire Agreement
	 	 	15	 
	8.9 Delays or Omissions
	 	 	15	 
	8.10 Severability
	 	 	15	 
	8.11 Counterparts
	 	 	15	 
	8.12 Telecopy Execution and Delivery
	 	 	15	 
	8.13 Jurisdiction; Venue
	 	 	16	 
	8.14 Further Assurances
	 	 	16	 
	8.15 Attorney’s Fees
	 	 	16	 
	8.16 Jury Trial
	 	 	16	 

ii

 

EXHIBITS

A            ENTERPRISE AGREEMENT

B            COMPLIANCE CERTIFICATE

C            SECRETARY’S CERTIFICATE

D            OPINION OF COUNSEL TO THE COMPANY

-iii-

 

OMNITURE, INC.

COMMON STOCK PURCHASE AGREEMENT

     THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of January 27, 2009
(“Effective Date”), and is among Omniture, Inc., a Delaware corporation (the “Company”), WPP
Luxembourg Gamma Three Sarl, a company formed under the laws of Luxembourg, with a principal place
of business located at 6 Rue Heine, L-1720 Luxembourg (the “Investor”) and, solely with respect to
Sections 5.2 and 8 hereof, WPP Group USA, Inc., a Delaware corporation (“WPP USA”).

     WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance
upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of
1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as
promulgated by the United States Securities and Exchange Commission (the “SEC”) under the
Securities Act;

     WHEREAS, the Investor wishes to purchase, and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, 2,852,578 shares (the “Shares”) of the Company’s common stock,
par value $0.001 per share (“Common Stock”).

     WHEREAS, contemporaneously with the execution and delivery of this Agreement, the parties
hereto are executing and delivering an Omniture Enterprise Channel Partner Agreement, substantially
in the form attached hereto as Exhibit A (the “Enterprise Agreement”).

     WHEREAS, the Company and the Investor wish to set forth the terms and conditions upon which
the Company will sell, and the Investor will purchase the Shares.

     NOW, THEREFORE, the parties hereto agree as follows:

SECTION 1

AUTHORIZATION, SALE AND ISSUANCE

     1.1 Authorization.  The Company will, prior to the Closing (as defined below), authorize the
sale and issuance of the Shares.

     1.2 Sale and Issuance of Shares.  Subject to the terms and conditions of this Agreement, the
Investor agrees to purchase, and the Company agrees to sell and issue to the Investor the Shares,
at a cash purchase price per share equal to $8.76, which the parties acknowledge represents 100% of
the arithmetic average of the closing prices for the Company’s Common Stock, as reported on the
Nasdaq Global Select Market for the five (5) consecutive trading days ending on the trading day
immediately prior to the date of Closing (the “Purchase Price”).

 

 

SECTION 2

CLOSING DATES AND DELIVERY

     2.1 Closing.  The purchase, sale and issuance of the Shares (the “Closing”) shall take place
at the offices of Wilson Sonsini Goodrich & Rosati, Professional Corporation One Market Street,
Spear Tower, Suite 3300 San Francisco, California 94105, on the Effective Date, or such other date
as the Company and the Investor shall agree.

     2.2 Delivery.  Within five (5) business days following the Closing, the Company will deliver
to the Investor a certificate registered in the Investor’s name representing the number of Shares
that the Investor is purchasing against payment of the Purchase Price, by wire transfer in
accordance with the Company’s instructions, provided that the Shares shall be, and shall for all
purposes be deemed to have been, issued as of the date of the Closing.

SECTION 3

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     Except as disclosed in writing in the (i) disclosure letter supplied by the Company to the
Investor dated as of the date hereof (the “Disclosure Letter”), the contents of the Disclosure
Letter will be deemed to be representations and warranties if made hereunder, (ii) the Company SEC
Reports (as defined below), or (iii) the Financial Statements (including the notes thereto)
(collectively, the “Disclosure Materials”), the Company represents and warrants to the Investor as
of the Effective Date as follows:

     3.1 Organization; Standing and Power; Charter Documents; Significant Subsidiaries. 

               (a) Organization; Standing and Power. The Company and each of its Significant
Subsidiaries (as defined in Rule 1.02 of Regulation S-X as promulgated by the SEC, each a
“Significant Subsidiary” and collectively, the “Significant Subsidiaries”) (i) is a corporation or
other organization duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization (except in the case of good standing for entities
organized under the laws of any jurisdiction that does not recognize such concept), (ii) has the
requisite power and authority to own, lease and operate its properties and to carry on its business
as now being conducted, and (iii) is duly qualified or licensed and in good standing to do business
in each jurisdiction in which the nature of its business or the ownership or leasing of its
properties makes such qualification or licensing necessary, other than in such jurisdictions where
the failure to so qualify or to be in good standing, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. For the purposes of this Agreement,
“Material Adverse Effect” means a material adverse effect on the consolidated financial position,
stockholders’ equity, results of operation, business or properties of the Company and its
subsidiaries taken as a whole other than any change, event or circumstance to the extent resulting
from or arising in connection with (A) economic or political conditions in general, including the
recent economic downturn, and effects on the software or online commerce industry and/or (B) the
securities or credit markets in general.

               (b) Charter Documents. The Company has delivered or made available to the Investor a
true and correct copy of the Company’s Amended and Restated Certificate of Incorporation (including
any Certificate of Designations) and Amended and Restated Bylaws, each as amended to date
(collectively, the “Company Charter Documents”) and each such instrument is in full force and
effect. The Company is not in

2

 

violation of any of the provisions of the Company Charter Documents,
except as would not reasonably be expected to have a Material Adverse Effect.

     3.2 Capital Structure. 

          (a) Capital Stock.

               (i) The authorized capital stock of the Company consists of: (i) 250,000,000 shares of Common
Stock, par value $0.001 per share and (ii) 10,000,000 shares of preferred stock, par value $0.001
per share (the “Preferred Stock”). At the close of business on January 22, 2009: (i) 73,007,740
shares of Common Stock were issued and outstanding, (ii) no shares of Common Stock were issued and
held by the Company in its treasury, and (iii) no shares of Preferred Stock were issued and
outstanding. Since the close of business on January 22, 2009 through the execution of this
Agreement, the Company has not issued any shares of Common Stock, other than pursuant to the
exercise of Company Options (as defined below) outstanding as of January 22, 2009 and granted
pursuant to the Company Stock Plans (as defined below).

               (ii) All of the outstanding shares of capital stock of the Company are and all of the Shares,
when issued and delivered and paid for in compliance with the provisions of this Agreement will be
validly issued, fully paid and nonassessable and will be free of any lien, charge or encumbrance
other than (x) limitations on transfer under this Agreement and under applicable laws, and (y) any
lien, charge or encumbrance resulting from actions or omissions of the Investor.

          (b) Stock Options. As of the close of business on January 22, 2009: (i) 13,147,937
shares of Common Stock were subject to issuance pursuant to outstanding options to purchase or
rights to purchase or acquire Common Stock or stock appreciation rights (the “Company Options”)
under the stock option, stock award, stock appreciation or phantom stock plans of the Company (the
“Company Stock Plans”), (ii) 4,804,233 shares of Common Stock were available for future issuance
under the Company Stock Plans, (iii) 1,563,622 shares of Common Stock were available for future
issuance under the employee stock purchase plan of the Company and (iv) 378,828 shares of Common
Stock were subject to issuance pursuant to outstanding options, rights or warrants to purchase
Common Stock issued other than pursuant to the Company Stock Plans and the Company employee stock
purchase plan. Since the close of business on January 22, 2009 through the execution of this
Agreement, no Company Options have been granted and no additional shares of Common Stock have been
reserved for future issuance pursuant to Company Options or other equity-based awards available for
grant under the Company Stock Plans. There are no outstanding or authorized phantom stock or other
similar rights (whether payable in stock, cash or other property) with respect to the Company.

          (c) Other Securities.

               (i) Except as otherwise set forth in Section 3.2(a) and (b) above, as the date hereof, there
are no securities, options, warrants, calls, rights, contracts, commitments, agreements,
instruments, arrangements, understandings, obligations or undertakings of any kind to which the
Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or
cause to be issued, delivered or sold, additional shares of capital stock, or other voting
securities of the Company, or obligating the Company to issue, grant, extend or enter into any such
security, option, warrant, call, right, commitment, agreement, instrument, arrangement,
understanding, obligation or undertaking.

               (ii) All outstanding shares of Common Stock, and all outstanding Company Options have been
issued and granted in compliance in all material respects with all applicable securities laws.

3

 

     3.3 Authority; Non-Contravention; Necessary Consents. 

          (a) Authority. The Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this Agreement and otherwise to carry out
its obligations hereunder. The execution and delivery of this Agreement by the Company and the
consummation by it of the transactions contemplated hereby have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company to
authorize this Agreement. This Agreement has been duly executed by the Company and, when delivered
in accordance with the terms hereof, will constitute the valid and binding obligation of the
Company enforceable against the Company in accordance with its terms, subject to bankruptcy,
insolvency, reorganization and other laws of general applicability relating to or affecting
creditors’ rights and general equity principles.

          (b) Non–Contravention. The execution and delivery of this Agreement by the Company
does not, and performance by the Company of its obligations hereunder will not: (i) conflict with
or violate the Company Charter Documents, (ii) subject to compliance with the requirements set
forth in Section 3.3(c), conflict with or violate any material law, administrative regulation or
ruling, or court decree applicable to the Company (“Legal Requirement”), or (iii) result in any
breach of or constitute a default (or an event that with notice or lapse of time or both would
become a default) under, or materially impair the Company’s rights or materially alter the rights
or obligations of any third party under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of any pledges, claims, liens, charges,
encumbrances, and security interests (collectively, “Liens”) on any of the properties or assets of
the Company pursuant to, any Material Contract except for any such conflicts, violations, breaches,
defaults or other occurrences which would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. For the purposes of this Agreement, the term “Material
Contract” means all agreements filed or incorporated by reference by the Company in the Company SEC
Reports pursuant to Section 10 of Item 601(b) of Regulation S-K promulgated under the Securities
Act to which the Company or any Significant Subsidiary is a party or to which any of the property
or assets of the Company or any Significant Subsidiary are subject.

          (c) Necessary Consents. No consent, approval, order or authorization of, or
registration, declaration or filing with any court, governmental agency or body (“Governmental
Entity”) is required to be obtained or made by the Company in connection with the execution and
delivery of this Agreement and the performance of the Company of its obligations hereunder, except:
(i) such consents, approvals, orders, authorizations, registrations, declarations and filings as
may be required under applicable federal, foreign and state securities (or related) laws and
satisfaction of such other requirements of the comparable applicable laws of other jurisdictions,
(ii) any filing of Form D under Regulation D under the Securities Act, (iii) such consents,
approvals, orders, authorizations, registrations, declarations and filings as may be required under
applicable state securities or “blue sky” laws and the securities laws of any foreign country and
(iv) such other consents, approvals, orders, authorizations, registrations, declarations or
filings, the failure of which to obtain would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.

     3.4 SEC Filings; Financial Statements. 

          (a) SEC Filings. The Company has filed all required registration statements,
prospectuses, reports, schedules, forms, statements and other documents (including exhibits and all
other information incorporated by reference) required to be filed by it with the SEC since
January 1, 2008. The Company has made available to the Investor all such registration statements,
prospectuses, reports, schedules, forms, statements and other documents in the form filed with the
SEC. All such required registration statements, prospectuses, reports, schedules, forms,
statements and other documents are referred to herein as the “Company SEC Reports.” As of their
respective dates, or, if amended or supplemented prior to the date

4

 

of this Agreement, as of the
date of such amendment or supplement, each Company SEC Report (i) complied in all material respects
with the requirements of the Securities Act, or the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), as the case may be, and the rules and regulations of the SEC thereunder
applicable to such Company SEC Report and (ii) did not at the time it was filed (or became
effective in the case of a registration statement), or if amended, supplemented or superseded by a
filing prior to the date of this Agreement then on the date of such superseding filing, amendment
or supplement, contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading.

          (b) Financial Statements. The financial statements of the Company included in the
Company SEC Reports (the “Financial Statements”) comply in all material respects with applicable
accounting requirements and the rules and regulations of the SEC with respect thereto as in effect
at the time of filing (or, if an amendment with respect to any such document was filed, when such
amendment was filed). The Financial Statements have been prepared in accordance with generally
accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in the Financial Statements or the notes thereto, and fairly
present in all material respects the financial position of the Company and its consolidated
subsidiaries as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end
audit adjustments. Since September 30, 2008 (the “Balance Sheet Date”) (a) there has been no
event, occurrence or development that has or that could reasonably be expected to result in a
Material Adverse Effect, (b) neither the Company nor any Significant Subsidiary has incurred any
liabilities (contingent or otherwise) other than (x) liabilities incurred in the ordinary course of
business and (y) liabilities not required to be reflected in the Financial Statements pursuant to
GAAP or required to be disclosed in filings made with the SEC, (c) the Company has not altered its
method of accounting or the identity of its independent registered public accounting firm and
(d) the Company has not declared or made any payment or distribution of cash or other property to
its stockholders or officers or directors (other than in compliance with existing Company Stock
Plans) with respect to its capital stock, or purchased, redeemed (or made any agreements to
purchase or redeem) any shares of its capital stock.

     3.5 Absence of Certain Changes or Events.  Since the Balance Sheet Date and other than
repurchases of Common Stock pursuant to the terms of equity awards under Company Options or Company
Stock Plans, there has not been (i) any declaration, setting aside or payment of any dividend on,
or other distribution (whether in cash, stock or property) in respect of, any of the Company’s
capital stock, or any purchase, redemption or other acquisition by the Company of any of the
Company’s capital stock or any other securities of the Company or any options, warrants, calls or
rights to acquire any such shares or other securities except for repurchases from employees
following their termination pursuant to the terms of their pre-existing stock option or purchase
agreements, or (ii) any split, combination or reclassification of any of the Company’s capital
stock.

     3.6 Compliance.  Neither the Company nor any of its Significant Subsidiaries is (i) in default
under or in violation of nor has the Company or any of its Significant Subsidiaries received
written notice of a claim that it is in default under any Material Contract, (ii) in violation of
any order of any Governmental Entity, or (iii) in violation of any statute, rule or regulation of
any Governmental Entity, in each case of clause (i), (ii) or (iii) above, except as would not
reasonably be expected to have or result in a Material Adverse Effect.

     3.7 Litigation.  There are no claims, suits, actions, judgments or proceedings pending or, to
the Company’s knowledge, threatened in writing against the Company or any of its Significant
Subsidiaries, by or before any court, governmental department, commission, agency, instrumentality
or authority, or any

5

 

arbitrator that seeks to restrain or enjoin the consummation of the
transactions contemplated by this Agreement or which would reasonably be expected, either
singularly or in the aggregate with all such claims, actions, judgments or proceedings, to have a
Material Adverse Effect. For the purposes of this Agreement, the term “knowledge” means the actual
knowledge of the executive officers of the Company.

     3.8 Brokers’ and Finders’ Fees.  The Company has not incurred, nor will it incur, directly or
indirectly, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with this Agreement or any transaction contemplated hereby, in any case, for
which the Company or any of its Subsidiaries will be liable or have any obligations.

SECTION 4

REPRESENTATIONS AND WARRANTIES OF THE INVESTOR

     The Investor hereby represents and warrants to the Company as follows:

     4.1 No Registration.  The Investor understands that the Shares have not been, and will not be,
registered under the Securities Act by reason of a specific exemption from the registration
provisions of the Securities Act, the availability of which depends upon, among other things, the
bona fide nature of the investment intent and the accuracy of the Investor’s representations as
expressed herein or otherwise made pursuant hereto.

     4.2 Investment Intent.  The Investor is acquiring the Shares for investment for its own
account, not as a nominee or agent, and not with the view to, or for resale in connection with, any
distribution thereof, and the Investor has no present intention of selling, granting any
participation in, or otherwise distributing the same. The Investor further represents that it does
not have any contract, undertaking, agreement or arrangement with any person or entity to sell,
transfer or grant participation to such person or entity or to any third person or entity with
respect to any of the Shares.

     4.3 Investment Experience .  The Investor has substantial experience in evaluating and investing in private placement
transactions of securities and acknowledges that the Investor can protect its own interests. The
Investor has such knowledge and experience in financial and business matters so that the Investor
is capable of evaluating the merits and risks of its investment in the Company.

     4.4 Speculative Nature of Investment.  The Investor understands and acknowledges that an
investment in the Company is highly speculative and involves substantial risks. The Investor can
bear the economic risk of the Investor’s investment and is able, without impairing the Investor’s
financial condition, to hold the Shares for an indefinite period of time and to suffer a complete
loss of the Investor’s investment.

     4.5 Access to Data.  The Investor has had an opportunity to ask questions of, and receive
answers from, the officers of the Company concerning this Agreement, the exhibits and schedules
attached hereto and the transactions contemplated hereby, as well as the Company’s business,
management and financial affairs, which questions were answered to its satisfaction. The Investor
believes that it has received all the information the Investor considers necessary or appropriate
for deciding whether to purchase the Shares. The Investor acknowledges that it is relying solely
on its own counsel and not on any statements or representations of the Company or its agents for
legal advice with respect to this investment or the transactions contemplated by this Agreement.

6

 

     4.6 Accredited Investor.  The Investor is an “accredited investor” within the meaning of
Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission under the
Securities Act.

     4.7 Residency.  The Investor’s principal place of business is correctly set forth on the
initial page of this Agreement.

     4.8 Rule 144.  The Investor acknowledges that the Shares must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is
available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act
which permit resale of shares purchased in a private placement subject to the satisfaction of
certain conditions. The Investor acknowledges that, in the event the applicable requirements of
Rule 144 are not met, registration under the Securities Act or an exemption from registration will
be required for any disposition of the Shares or the underlying Common Stock.

     4.9 Authorization. 

          (a) The Investor has all requisite power and authority to execute and deliver this Agreement,
to purchase the Shares hereunder and to carry out and perform its obligations under the terms of
this Agreement. All action on the part of the Investor necessary for the authorization, execution,
delivery and performance of this Agreement has been taken or will be taken prior to the Closing.

          (b) This Agreement, when executed and delivered by the Investor, will constitute valid and
legally binding obligations of the Investor, enforceable in accordance with their terms except:
(i) as limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization,
moratorium and any other laws of general application affecting or relating to enforcement of
creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies or by general principles of equity.

          (c) No consent, approval, authorization, order, filing, registration or qualification of or
with any court, governmental authority or third person is required to be obtained by the Investor
in connection with the execution and delivery of this Agreement by the Investor or the performance
of the Investor’s obligations hereunder or thereunder.

     4.10 Brokers or Finders.  The Investor has not engaged any brokers, finders or agents, and the
Company has not and will not incur, directly or indirectly, as a result of any action taken by the
Investor, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with this Agreement.

     4.11 Tax Advisors.  The Investor has reviewed with its own tax advisors the U.S. federal,
state, local and foreign tax consequences of this investment and the transactions contemplated by
this Agreement. With respect to such matters, the Investor relies solely on such advisors and not
on any statements or representations of the Company or any of its agents, written or oral. The
Investor understands that it (and not the Company) shall be responsible for its own tax liability
that may arise as a result of this investment or the transactions contemplated by this Agreement.

     4.12 Representations by Non-United States persons.  The Investor hereby represents that the
Investor is satisfied as to the full observance of the laws of the Investor’s jurisdiction in
connection with any invitation to subscribe for the Shares and or any use of this Agreement and the
Warrant (as defined in the Enterprise Agreement), including (i) the legal requirements within the
Investor’s jurisdiction for the purchase

7

 

of the Shares, the issuance of the Warrant and the
purchase of the Warrant Shares (as defined in the Enterprise Agreement, the “Warrant Shares”),
(ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other
consents that may need to be obtained and (iv) the income tax and other tax consequences, if any,
that may be relevant to the purchase, holding, redemption, sale or transfer of such securities. The
Investor’s subscription and payment for, and the Investor’s continued beneficial ownership of, the
Shares and the Warrant Shares will not violate any applicable securities or other laws of the
Investor’s jurisdiction.

SECTION 5

ADDITIONAL COVENANTS

     5.1 Restrictions on Transfer.  The Shares and the Warrant Shares shall not be Transferred,
except upon the conditions specified in this Agreement. The Investor will cause any transferee who
receives the Shares or Warrant Shares in a
Transfer permitted under this Agreement other than a sale pursuant to (i) an effective
registration statement under the Securities Act or (ii) Rule 144 under the Securities Act to assume
in writing the obligations and restrictions of the Investor under this Agreement, and the other
restrictions set forth in this Section 5. For the purpose of this Agreement, the terms “Transfer,”
“Transferring,” “Transferred,” or words of similar import, mean and include any sale, assignment,
encumbrance, hypothecation, pledge, conveyance in trust, gift, transfer by bequest, devise or
descent, or other transfer or disposition of any kind, including but not limited to transfers to
receivers, levying creditors, trustees or receivers in bankruptcy proceedings or general assignees
for the benefit of creditors, whether voluntary or by operation of law, directly or indirectly.

     5.2 Standstill.  For a period commencing on the Effective Date and ending on July 27, 2010,
neither the Investor nor WPP USA, whether directly or indirectly through one or more
intermediaries, including any of their respective Affiliates or Representatives of any of the
foregoing (but, as to Representatives, only if acting in a representative capacity) shall, without
the prior written consent of the Company or its Board of Directors:

          (a) acquire, offer to acquire, or agree to acquire, directly or indirectly, by purchase or
otherwise, any voting securities or direct or indirect rights to acquire any voting securities of
the Company or any subsidiary thereof, or of any successor to or person in control of the Company,
or any assets of the Company or any subsidiary or division thereof or of any such successor or
controlling person; notwithstanding the foregoing, the Investor may acquire voting securities of
the Company amounting to not more than five percent (5%) of the Company’s outstanding voting
securities (in addition to the Shares purchased under this Agreement and any Warrant Shares
acquired pursuant to the Enterprise Agreement);

          (b) make, or in any way participate, directly or indirectly, in any “solicitation” of
“proxies” to vote (as such terms are used in the rules of the SEC), or seek to advise or influence
any person or entity with respect to the voting of any voting securities of the Company;

          (c) make any public announcement with respect to, or submit a proposal for, or offer of (with
or without conditions) any extraordinary transaction involving the Company or any of its securities
or assets;

          (d) form, join or in any way participate in a “group” as defined in Section 13(d)(3) of the
Exchange Act, in connection with any of the foregoing;

8

 

          (e) otherwise act or seek to control or influence the management, Board of Directors or
policies of the Company;

          (f) take any action that could reasonably be expected to require the Company to make a public
announcement regarding the possibility of any of the events described in clauses (a) through (e)
above; or

          (g) request the Company or any of its Affiliates or Representatives, directly or indirectly,
to amend or waive any provision of this paragraph.

     Notwithstanding the foregoing, (1) nothing in this Section 5.2 shall prohibit the Investor or
its Affiliates or Representatives from making, or require the Investor or any of its
Representatives to obtain the consent of the Company or its Board of Directors to make, one or more
proposals to the Company or its Board of Directors or any committee thereof to acquire, offer to
acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, 100% of the voting
securities of the Company, provided that such
proposal would not be required to be made public by Investor, WPP USA, or any of their
respective Affiliates or the Company by law, rule, regulation or the requirements of any exchange
on which the Company’s stock is listed, and (2) the restrictions contained in this Section 5.2
shall become inoperative upon the earlier of (i) the Company entering into a definitive agreement
with respect to a Combination (as defined below); or (ii) the expiration of ten (10) business days
following the commencement of an unsolicited tender or exchange offer involving the Company or its
securities made by any third party other than Investor, WPP USA, or any of their respective
Affiliates. For purposes of this Section 5.2, when two or more persons act as a partnership,
limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing
of securities of a Company, such syndicate or group shall be deemed a “person”.

     For the purposes of this Agreement, (a) the term “Combination” means a transaction or series
of related transactions in which (i) a “person” acquires, directly or indirectly, securities
representing 50% or more of the voting power of the outstanding securities of the Company or
properties or assets constituting 50% or more of the consolidated assets of the Company and its
subsidiaries or (ii) the Company issues securities representing 50% or more of its total voting
power, including, in the case of clauses (i) and (ii), by way of a merger or other business
combination with the Company or any of its subsidiaries; (b) the term “Representative” means as to
any person, its directors, officers, employees, agents and advisors (including, without limitation,
financial advisors, attorneys and accountants); and (ii) “person” shall be broadly interpreted to
include, without limitation, any corporation, company, partnership, other entity or individual, and
(c) the term “Affiliate” means as to any person, any entity in which such person owns or controls,
directly or indirectly, a majority of the outstanding shares, securities or equity interests of
such entity or has the power to elect or appoint, by agreement or otherwise, a majority of the
board of directors (or comparable governing body) of such entity and/or any parent company or
entity that owns or controls a majority of the outstanding shares, securities, or equity interests
of such person or has the power to elect or appoint, by agreement or otherwise, a majority of the
board of directors (or comparable governing body) of such person, or any person that is under
common control with such person, including international Affiliates of such person.

     5.3 Market Standoff. 

          (a) Until July 27, 2010 (the “Market Standoff Period”) the Investor will not, directly or
indirectly, offer, sell, pledge, contract to sell (including any short sale), grant any option to
purchase or otherwise dispose of any shares of Common Stock (including, without limitation, shares
of Common Stock of the Company which may be deemed to be beneficially owned by the undersigned on
the date hereof in accordance with the rules and regulations of the SEC, shares of Common Stock
which may be issued upon exercise of a stock option or warrant and any other security convertible
into or exchangeable for Common

9

 

Stock) or enter into any Hedging Transaction (as defined below)
relating to the Common Stock (each of the foregoing referred to as a “Disposition”) during the
Market Standoff Period. The foregoing restriction is expressly intended to preclude the
undersigned from engaging in any Hedging Transaction or other transaction which is designed to or
reasonably expected to lead to or result in a Disposition during the Market Standoff Period even if
the securities would be disposed of by someone other than the undersigned. “Hedging Transaction”
means any short sale (whether or not against the box) or any purchase, sale or grant of any right
(including, without limitation, any put or call option) with respect to any security (other than a
broad-based market basket or index) that includes, relates to or derives any significant part of
its value from the Common Stock.

          (b) If requested by the Company and an underwriter of Common Stock (or other securities) of
the Company, Investor shall not sell or otherwise transfer, make any short sale of, grant any
option for the purchase of, or enter into any hedging or similar transaction with the same economic
effect as a
sale, of any Common Stock (or other securities) of the Company held by Investor (other than
those included in the registration) during the 90-day period following the effective date of a
registration statement of the Company filed under the Securities Act (or such other period as may
be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the
publication or other distribution of research reports and (ii) analyst recommendations and
opinions, including, but not limited to, the restrictions contained in Rule 2711 of the Financial
Industry Regulatory Authority or Rule 472(f)(4) of the New York Stock Exchange, or any successor
provisions or amendments thereto), provided that all officers and directors of the Company are
bound by and have entered into an agreement in substantially the same form covering all outstanding
voting securities of the Company of which they are deemed to have beneficial ownership for purposes
of Section 13(d) of the Exchange Act and the rules promulgated by the SEC thereunder. The
obligations described in this Section 5.3(b) shall not apply to a registration relating solely to
employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the
future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be
promulgated in the future. The Company may impose stop-transfer instructions and may stamp each
such certificate with the second legend set forth in Section 5.4 with respect to the shares of
Common Stock (or other securities) subject to the foregoing restriction until the end of such
90-day (or other) period. Investor agrees to execute a market standoff agreement with said
underwriters in customary form consistent with the provisions of this Section 5.3(b); provided that
all officers and directors of the Company are bound by and have entered into an agreement in
substantially the same form covering all outstanding voting securities of the Company of which they
are deemed to have beneficial ownership for purposes of Section 13(d) of the Exchange Act and the
rules promulgated by the SEC thereunder. Any discretionary waiver or termination of the
restrictions of any or all of such agreements by the Company or the underwriters shall apply to the
Investor.

     5.4 Restrictive Legends.  Each certificate representing the Shares shall be stamped or
otherwise imprinted with the following or similar legends:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF
ANY STATE, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE
STATE SECURITIES LAWS, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AND ITS
COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.

10

 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS
SET FORTH IN A COMMON STOCK PURCHASE AGREEMENT TO WHICH THE ORIGINAL
HOLDER OF THESE SHARES WAS A PARTY, A COPY OF WHICH MAY BE OBTAINED AT
THE PRINCIPAL OFFICE OF THE COMPANY. SUCH RESTRICTIONS ARE BINDING ON
TRANSFEREES OF THESE SHARES.

     The Investor consents to the making of a notation by the Company on its records and giving
instructions to any transfer agent of its capital stock in order to implement the restrictions on
transfer established in this Agreement.

     5.5 Notice of Proposed Transfers. No Transfer (other than (i) a sale made pursuant to a registration statement filed under
the Securities Act and declared effective by the SEC for which no stop order has been issued and is
then existing or (ii) a sale made in accordance with the applicable provisions of Rule 144) of
Shares or Warrant Shares shall be made by the Investor to any person unless such person shall first
agree in writing to be bound by the restrictions of this Agreement, including without limitation
this Section 5. Prior to any proposed Transfer of any Shares or any Warrant Shares, unless there
is in effect a registration statement under the Securities Act covering the proposed Transfer or
such Transfer is made pursuant to Rule 144, the holder thereof shall give written notice to the
Company of such holder’s intention to effect such Transfer. Each such notice shall describe the
manner and circumstances of the proposed Transfer, sale, assignment or pledge in reasonable detail,
and, if requested by the Company, the Investor shall also provide, at the Investor’s expense, a
written opinion of legal counsel (who shall be, and whose legal opinion shall be, reasonably
satisfactory to the Company) addressed to the Company, to the effect that the proposed Transfer of
the Shares or Warrant Shares may be effected without registration under the Securities Act and
under applicable state securities laws and regulations. Subject to the terms of this Section 5,
upon delivery to the Company of such notice and, if required, such opinion, the Investor shall be
entitled to Transfer such Shares or Warrant Shares, as the case may be, in accordance with the
terms of such notice. Each certificate evidencing the Shares or the Warrant Shares transferred as
above provided shall bear, except if such transfer is made pursuant to Rule 144 or pursuant to an
effective registration statement, the appropriate restrictive legend set forth in Section 5.4 above
or in the Warrant (as defined in the Enterprise Agreement), as the case may be, except that such
certificate shall not bear such restrictive legend if, in the opinion of counsel for Investor and
counsel for the Company, such legend is not required in order to establish or ensure compliance
with the provisions of the Securities Act and this Agreement. Without limiting the foregoing, the
Company shall not permit any Transfer of the Shares or the Warrant Shares on its books and records
and any attempted Transfer of any Shares or Warrant Shares shall be void unless or until the person
or entity to whom such Shares or Warrant Shares are to be Transferred shall have executed and
delivered to the Company a written agreement satisfactory to the Company to be bound by all the
terms of this Agreement.

11

 

SECTION 6

CONDITIONS TO INVESTOR’S OBLIGATIONS TO CLOSE

     The Investor’s obligation to purchase the Shares at the Closing is subject to the fulfillment
on or before the Closing of each of the following conditions, unless waived by the Investor:

     6.1 Representations and Warranties.  Except as disclosed in writing in the Disclosure
Materials, the representations and warranties made by the Company in Section 3 shall be true and
correct as of the date of the Closing Date.

     6.2 Covenants.  The Company shall have performed or complied with all covenants, agreements
and conditions contained in this Agreement to be performed or complied with by the Company on or
prior to the Closing in all material respects.

     6.3 Qualifications.  All authorizations, approvals or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are required in connection
with the lawful issuance and sale of the Shares
pursuant to this Agreement, except for such as may be properly filed subsequent to Closing,
shall be obtained and effective as of the Closing.

     6.4 Closing Deliverables.  The Company shall have delivered to counsel to the Investor the
following:

          (a) a duly executed copy of this Agreement.

          (b) a duly executed copy of the Enterprise Agreement.

          (c) a certificate executed by the Chief Executive Officer, President or Chief Financial
Officer of the Company on behalf of the Company, in substantially the form attached hereto as
Exhibit B, certifying the satisfaction of the conditions to closing listed in Sections 6.1
and 6.2.

          (d) a certificate of the Secretary of State of the State of Delaware, dated as of a date
within five days of the date of the Closing, with respect to the good standing of the Company.

          (e) a certificate of the Company executed by the Company’s Secretary, in substantially the
form attached hereto as Exhibit C, attaching and certifying to the truth and correctness of
(1) the Amended and Restated Certificate of Incorporation of the Company, (2) the Amended and
Restated Bylaws of the Company and (3) the board resolutions adopted in connection with the
transactions contemplated by this Agreement.

          (f) an opinion from Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel to the
Company, dated as of the Closing, in substantially the form attached hereto as Exhibit D.

12

 

SECTION 7

CONDITIONS TO COMPANY’S OBLIGATION TO CLOSE

     The Company’s obligation to sell and issue the Shares at the Closing is subject to the
fulfillment on or before such Closing of the following conditions, unless waived by the Company:

     7.1 Representations and Warranties.  The representations and warranties made by the Investor
in such Closing in Section 4 shall be true and correct when made and shall be true and correct as
of the date of the Closing.

     7.2 Covenants.  The Investor shall have performed or complied with all covenants, agreements
and conditions contained in the Agreement to be performed or complied with by the Investor on or
prior to the date of such Closing in all material respects.

     7.3 Compliance with Securities Laws.  The Company shall be satisfied that the offer and sale
of the Shares shall be qualified or exempt from registration or qualification under all applicable
federal and state securities laws (including receipt by the Company of all necessary blue sky law
permits and qualifications required by any state, if any).

     7.4 Qualifications.  All authorizations, approvals or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are required in connection
with the lawful issuance and sale of the Shares pursuant to this Agreement, except for such as may
be properly filed subsequent to Closing, shall be obtained and effective as of the Closing.

     7.5 Closing Deliverables.  The Investor shall have delivered to counsel to the Company the
following:

          (a) a duly executed copy of this Agreement.

          (b) a duly executed copy of the Enterprise Agreement.

          (c) Twenty-five million dollars ($25,000,000.00) by wire transfer of immediately available
funds to the account specified by the Company.

SECTION 8

MISCELLANEOUS

     8.1 Amendment.  Except as expressly provided herein, neither this Agreement nor any term
hereof may be amended, waived, discharged or terminated other than by a written instrument
referencing this Agreement and signed by the Company and the Investor.

     8.2 Notices.  All notices and other communications required or permitted hereunder shall be in
writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or
otherwise delivered by hand, messenger or courier service addressed:

13

 

          (a) if to the Investor, to the attention of Lance Maerov, Senior Vice President, Corporate
Development, WPP Group USA, Inc., at 125 Park Avenue, 4th Floor, New York, New York
10017-5529, Facsimile Number: (212) 632-2453, or at such other current address or facsimile number
as the Investor shall have furnished to the Company, with a copy (which shall not constitute
notice) to Curt C. Myers, Davis & Gilbert LLP, 1740 Broadway, New York, New York 10019, Facsimile
Number (212) 468-4888; or

          (b) if to the Company, to the attention of the Chief Executive Officer of the Company at 550
East Timpanogos Circle, Orem, Utah 84097, Facsimile Number: (801) 722.7005 or at such other current
address or facsimile number as the Company shall have furnished to the Investor, with copies (which
shall not constitute notice) to (1) the Company’s Chief Legal Officer at 550 East Timpanogos
Circle, Orem, Utah 84097, Facsimile Number: (801) 722.7005 or at such other current address or
facsimile number as the Company shall have furnished to the Investor; and (2) Robert G. O’Connor,
Wilson Sonsini Goodrich & Rosati, P.C., One Market Street, Spear Tower, Suite 3300, San Francisco,
California 94105, Facsimile Number: (415) 947.2099

     Each such notice or other communication shall for all purposes of this Agreement be treated as
effective or having been given (i) if delivered by hand, messenger or courier service, when
delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid,
specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if
sent via mail, at the earlier of its receipt or five days after the same has been deposited in a
regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as
aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer, if sent during
normal business hours of the recipient, or if not sent during normal business hours of the
recipient, then on the recipient’s next business day, in either case with a copy of such notice or
other communication sent by hand, messenger, courier service or registered or certified mail within
three (3) business days.

     8.3 Governing Law.  This Agreement shall be governed in all respects by the internal laws of
the State of Delaware as applied to agreements entered into among Delaware residents to be
performed entirely within Delaware, without regard to principles of conflicts of law.

     8.4 Expenses.  The Company and the Investor shall each pay the fees and expenses of their own
respective counsel, advisers, accountants, and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution, delivery and
performance of this Agreement.

     8.5 Disclosure.  This Agreement and its terms shall be held in strict confidentiality by each
party, and neither the Company nor the Investor (including, without limitation, employees,
advisors, representatives, affiliates or agents of either party) shall disclose or reveal in any
way this Agreement or any of the terms hereof to any third party without the prior written consent
of the other party. Notwithstanding the foregoing and based on consultation with inside or outside
legal counsel, either party may disclose information concerning this Agreement as required by the
rules, orders or regulations of a government or governmental agency (including, without limitation,
any rule, regulation or policy of the SEC or any national securities exchange, market or automated
quotation system on which such party’s securities are listed or quoted). Prior to any such
disclosure however, either party will promptly notify the other party of the scope of and basis for
such disclosure. In the event that either party determines that this Agreement or a portion
thereof is required to be filed with the SEC, such party will, if requested by the other party, use
commercially reasonable efforts to obtain confidential treatment for the portions of this Agreement
for which the other party requested such confidential treatment. Notwithstanding the foregoing,
the Company and the Investor intend to issue a press release on or shortly after the date of
Closing in a form mutually acceptable to both the Company and the Investor.

14

 

     8.6 Survival.  The representations, warranties, covenants and agreements made in this
Agreement shall survive any investigation made by any party hereto and the closing of the
transactions contemplated hereby for one year from the date of the Closing.

     8.7 Successors and Assigns.  This Agreement, and any and all rights, duties and obligations hereunder, shall not be
assigned, transferred, delegated or sublicensed by the Investor without the prior written consent
of the Company. Any attempt by an Investor without such permission to assign, transfer, delegate or
sublicense any rights, duties or obligations that arise under this Agreement shall be void. Subject
to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall
inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto.

     8.8 Entire Agreement.  This Agreement, the Enterprise Agreement, including and that certain
Letter Agreement by and between the Company and the Investor dated January 16, 2009 (the
“Confidentiality Agreement”), together with all schedules, exhibits, annexes hereto and thereto and
the Disclosure Letter, constitute the full and entire understanding and agreement between the
parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any
other party in any manner with regard to the subjects hereof or thereof by any warranties,
representations or covenants except as specifically set forth herein or therein.

     8.9 Delays or Omissions.  Except as expressly provided herein, no delay or omission to
exercise any right, power or remedy accruing to any party to this Agreement upon any breach or
default of any other party under this Agreement shall impair any such right, power or remedy of
such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default,
or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any party of any breach or default under this Agreement, or any waiver on
the part of any party of any provisions or conditions of this Agreement, must be in writing and
shall be effective only to the extent specifically set forth in such writing. All remedies, either
under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be
cumulative and not alternative.

     8.10 Severability.  If any provision of this Agreement becomes or is declared by a court of
competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such
provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such
court will replace such illegal, void or unenforceable provision of this Agreement with a valid and
enforceable provision that will achieve, to the extent possible, the same economic, business and
other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall
be enforceable in accordance with its terms.

     8.11 Counterparts.  This Agreement may be executed in any number of counterparts, each of
which shall be enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one instrument.

     8.12 Telecopy Execution and Delivery.  A facsimile, telecopy or other reproduction of this
Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or
any similar electronic transmission device pursuant to which the signature of or on behalf of such
party can be seen. Such execution and delivery shall be considered valid, binding and effective for
all purposes. At the request of any party hereto, all parties hereto
agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy
or other reproduction hereof.

15

 

     8.13 Jurisdiction; Venue.  With respect to any disputes arising out of or related to this
Agreement, the parties consent to the exclusive jurisdiction of, and venue in, the state courts in
Salt Lake County in the State of Utah (or in the event of exclusive federal jurisdiction, the
courts of the District of Utah).

     8.14 Further Assurances.  Each party hereto agrees to execute and deliver, by the proper
exercise of its corporate, limited liability company, partnership or other powers, all such other
and additional instruments and documents and do all such other acts and things as may be necessary
to more fully effectuate this Agreement.

     8.15 Attorney’s Fees.  In the event that any suit or action is instituted to enforce any
provisions in this Agreement, the prevailing party in such dispute shall be entitled to recover
from the losing party such reasonable fees and expenses of attorneys and accountants, which shall
include, without limitation, all fees, costs and expenses of appeals.

     8.16 Jury Trial.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN
CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.

(signature page follows)

16

 

     The parties are signing this Common Stock Purchase Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	“COMPANY”	 	 
	 
	 	 	 	 	 	 
	 	 	OMNITURE, INC.,

a Delaware corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Joshua G. James	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Joshua G. James

Title: President and Chief Executive Officer	 	 

(Signature page to the Common Stock Purchase Agreement)

 

 

     The parties are signing this Common Stock Purchase Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	“INVESTOR”	 	 
	 
	 	 	 	 	 	 
	 	 	WPP LUXEMBOURG GAMMA THREE SARL,

a company formed under the laws of Luxembourg	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Thiemy Lenders
 

	 	 
	 	 	Name: Thiemy Lenders	 	 
	 	 	Title: Manager	 	 

(Signature page to the Common Stock Purchase Agreement)

 

 

     The parties are signing this Common Stock Purchase Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	“WPP”	 	 
	 
	 	 	 	 	 	 
	 	 	WPP GROUP USA, INC.*

a Delaware corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Kevin Farewell
 

	 	 
	 	 	Name: Kevin Farewell

Title: Assistant Treasurer, VP and Senior Tax Counsel	 	 

 

	*	 	Solely for the purposes of Sections 5.2 and 8.

(Signature page to the Common Stock Purchase Agreement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]